[1] Zeng N, Duan W, Chen S, et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis. Hepatol Int, 2019,13:788-799. [2] EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol, 2017,67:145-172. [3] Lindor K D, Bowlus C L, Boyer J, et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology, 2019,69:394-419. [4] 张奉春, 王立, 帅宗文, 等. 原发性胆汁性胆管炎诊疗规范(2021). 中华内科杂志, 2021,60:709-715. [5] 陈成伟, 成军, 窦晓光, 等. 原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015). 临床肝胆病杂志, 2015,31:1980-1988. [6] 人类年龄划分又有新标准. 民俗研究, 2001:26. [7] Carey E J, Ali A H, Lindor K D. Primary biliary cirrhosis. Lancet, 2015,386:1565-1575. [8] Nakamura M. Clinical significance of autoantibodies in primary biliary cirrhosis. Semin Liver Dis, 2014,34:334-340. [9] Terziroli B B, Mieli-Vergani G, Vergani D. The clinical usage and definition of autoantibodies in immune-mediated liver disease: A comprehensive overview. J Autoimmun, 2018,95:144-158. [10] 中国医师协会风湿免疫科医师分会自身抗体检测专业委员会, 国家风湿病数据中心, 国家皮肤与免疫疾病临床医学研究中心. 自身免疫性肝病相关自身抗体检测的临床应用专家共识. 中华内科杂志, 2021:619-625. [11] Hu C, Deng C, Song G, et al. Prevalence of autoimmune liver disease related autoantibodies in Chinese patients with primary biliary cirrhosis. Dig Dis Sci, 2011,56:3357-3363. [12] John B V, Dahman B, Deng Y, et al. Rates of Decompensation, Hepatocellular Carcinoma and Mortality in AMA-Negative Primary Biliary Cholangitis Cirrhosis. Liver Int, 2021. [13] Can?ado G, Braga M H, Ferraz M, et al. Anti-mitochondrial Antibody-Negative Primary Biliary Cholangitis Is Part of the Same Spectrum of Classical Primary Biliary Cholangitis. Dig Dis Sci, 2021. [14] Sakauchi F, Mori M, Zeniya M, et al. Antimitochondrial antibody negative primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid. J Epidemiol, 2006,16:30-34. [15] Tang L, Zhong R, He X, et al. Evidence for the association between IgG-antimitochondrial antibody and biochemical response to ursodeoxycholic acid treatment in primary biliary cholangitis. J Gastroenterol Hepatol, 2017,32:659-666. [16] Yamagiwa S, Kamimura H, Takamura M, et al. Autoantibodies in primary biliary cirrhosis: recent progress in research on the pathogenetic and clinical significance. World J Gastroenterol, 2014,20:2606-2612. |